{"generic":"Eslicarbazepine Acetate","drugs":["Aptiom","Eslicarbazepine Acetate"],"mono":{"0":{"id":"930358-s-0","title":"Generic Names","mono":"Eslicarbazepine Acetate"},"1":{"id":"930358-s-1","title":"Dosing and Indications","sub":[{"id":"930358-s-1-4","title":"Adult Dosing","mono":"<ul><li>discontinue gradually to reduce risk of increased seizure frequency and status epilepticus<\/li><li><b>Partial seizure; Adjunct:<\/b> initial, 400 mg ORALLY once daily for 1 week; may initiate treatment at 800 mg ORALLY once daily if need for seizure reduction outweighs increased risk of adverse reactions during initiation<\/li><li><b>Partial seizure; Adjunct:<\/b> maintenance, 800 mg ORALLY once daily; may increase to MAX of 1200 mg ORALLY once daily after 1 week, but adverse reactions may be increased at this dosage<\/li><\/ul>"},{"id":"930358-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients younger than 18 years "},{"id":"930358-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, CrCl less than 50 mL\/min:<\/b> initial dose, 200 mg ORALLY once daily for 2 weeks followed by maintenance dose of 400 mg ORALLY once daily; maximum recommended maintenance dosage of 600 mg orally once daily may benefit some patients<\/li><li><b>hepatic impairment, mild to moderate:<\/b> no dose adjustment required<\/li><li><b>hepatic impairment, severe:<\/b> use not recommended<\/li><li><b>adjunctive therapy with oxcarbazepine:<\/b> use not recommended<\/li><li><b>adjunctive therapy with carbamazepine:<\/b> dose adjustment of eslicarbazepine or carbamazepine may be needed for efficacy or tolerability<\/li><li><b>adjunctive therapy with other enzyme-inducing antiepileptic drugs (ie, phenobarbital, phenytoin, primidone):<\/b> dosage of eslicarbazepine may need to be increased<\/li><li><b>gender:<\/b> no dosage adjustments needed<\/li><\/ul>"},{"id":"930358-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Partial seizure; Adjunct<br\/>"}]},"3":{"id":"930358-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930358-s-3-9","title":"Contraindications","mono":"hypersensitivity to eslicarbazepine acetate, oxcarbazepine, or any component of the product <br\/>"},{"id":"930358-s-3-10","title":"Precautions","mono":"<ul><li>abrupt discontinuation may increase seizure frequency; withdraw gradually<\/li><li>anaphylaxis and angioedema have been reported; discontinue use if occur<\/li><li>dermatological reactions, serious (eg, Stevens-Johnson syndrome), have been reported; discontinue use unless clearly not drug related; do not initiate therapy if previous dermatologic reaction has occurred while on eslicarbazepine or oxcarbazepine<\/li><li>drug reaction with eosinophilia and systemic symptoms (DRESS) (ie, multiorgan hypersensitivity), potentially fatal, has been reported; discontinue and do not resume use if occurs and an alternative etiology cannot be determined; do not initiate therapy if previous DRESS has occurred while on eslicarbazepine or oxcarbazepine<\/li><li>hepatic injury (elevated transaminases and bilirubin) has been reported; monitoring recommended; discontinue use if jaundice or laboratory evidence of significant liver injury occurs<\/li><li>hepatic impairment, severe; use not recommended<\/li><li>hyponatremia has been reported; increased risk with increasing dose or concomitant hyponatremia-inducing drugs; consider monitoring; dose reduction and\/or discontinuation may be necessary<\/li><li>neurologic events, dose-dependent (eg, dizziness, gait, coordination, cognitive and visual disturbances, fatigue, and somnolence) have been reported; increased risk with large doses, during titration, elderly (60 years or older), and concomitant carbamazepine<\/li><li>renal impairment, moderate and severe (CrCl less than 50 mL\/min); dose adjustment required<\/li><li>suicidal ideation and behavior have been reported with antiepileptic active substances; monitoring recommended<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930358-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930358-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930358-s-4","title":"Drug Interactions","sub":{"1":{"id":"930358-s-4-14","title":"Major","mono":"<ul><li>Abiraterone (theoretical)<\/li><li>Ado-Trastuzumab Emtansine (theoretical)<\/li><li>Alfentanil (theoretical)<\/li><li>Alprazolam (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amlodipine (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Aprepitant (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Artemether (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Atorvastatin (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Brentuximab Vedotin (theoretical)<\/li><li>Brinzolamide (theoretical)<\/li><li>Bromocriptine (theoretical)<\/li><li>Budesonide (theoretical)<\/li><li>Buprenorphine (theoretical)<\/li><li>Buspirone (theoretical)<\/li><li>Cabazitaxel (theoretical)<\/li><li>Cabozantinib (theoretical)<\/li><li>Canagliflozin (theoretical)<\/li><li>Carbamazepine (probable)<\/li><li>Carisoprodol (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clobazam (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clopidogrel (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclophosphamide (theoretical)<\/li><li>Cyclosporine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Daclatasvir (theoretical)<\/li><li>Darifenacin (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Delavirdine (theoretical)<\/li><li>Dexamethasone (theoretical)<\/li><li>Diazepam (theoretical)<\/li><li>Dihydroergotamine (theoretical)<\/li><li>Docetaxel (theoretical)<\/li><li>Dolutegravir (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Doxepin (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Dutasteride (theoretical)<\/li><li>Eletriptan (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Elvitegravir (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Eplerenone (theoretical)<\/li><li>Ergotamine (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Esomeprazole (theoretical)<\/li><li>Estradiol (theoretical)<\/li><li>Everolimus (theoretical)<\/li><li>Felodipine (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Fluticasone (theoretical)<\/li><li>Fosamprenavir (theoretical)<\/li><li>Fosphenytoin (probable)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imatinib (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lacosamide (theoretical)<\/li><li>Lansoprazole (theoretical)<\/li><li>Letrozole (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Lomitapide (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Losartan (theoretical)<\/li><li>Lovastatin (theoretical)<\/li><li>Lurasidone (theoretical)<\/li><li>Maraviroc (theoretical)<\/li><li>Medroxyprogesterone (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Mephenytoin (theoretical)<\/li><li>Meprobamate (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Midazolam (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nateglinide (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nifedipine (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Nisoldipine (theoretical)<\/li><li>Olaparib (theoretical)<\/li><li>Omeprazole (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Orlistat (probable)<\/li><li>Ospemifene (theoretical)<\/li><li>Oxycodone (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Palbociclib (theoretical)<\/li><li>Pantoprazole (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Perampanel (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (probable)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Ponatinib (theoretical)<\/li><li>Prednisolone (theoretical)<\/li><li>Prednisone (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Progesterone (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Propranolol (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Rabeprazole (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Regorafenib (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rilpivirine (theoretical)<\/li><li>Riociguat (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Roflumilast (theoretical)<\/li><li>Rosuvastatin (probable)<\/li><li>Salmeterol (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Saxagliptin (theoretical)<\/li><li>Sildenafil (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Simvastatin (established)<\/li><li>Sirolimus (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Tamoxifen (theoretical)<\/li><li>Tamsulosin (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Temsirolimus (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Ticagrelor (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Tolvaptan (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Tramadol (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Triamcinolone (theoretical)<\/li><li>Triazolam (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Verapamil (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vilazodone (theoretical)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><li>Zaleplon (theoretical)<\/li><li>Zileuton (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><li>Zolpidem (theoretical)<\/li><\/ul>"},"2":{"id":"930358-s-4-15","title":"Moderate","mono":"<ul><li>Ethinyl Estradiol (probable)<\/li><li>Levonorgestrel (probable)<\/li><li>Warfarin (established)<\/li><\/ul>"}}},"5":{"id":"930358-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Nausea (10% to 16%), Vomiting (6% to 10%)<\/li><li><b>Neurologic:<\/b>Ataxia (4% to 6%), Dizziness (20% to 28%), Headache (13% to 15%), Somnolence (11% to 18%), Tremor (2% to 4%), Vertigo (2% to 6%)<\/li><li><b>Ophthalmic:<\/b>Blurred vision (5% to 6%), Diplopia (9% to 11%)<\/li><li><b>Other:<\/b>Fatigue (4% to 7%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Drug-induced eosinophilia<\/li><li><b>Hepatic:<\/b>Increased liver enzymes, Serum bilirubin raised<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Drug hypersensitivity syndrome<\/li><li><b>Psychiatric:<\/b>Suicidal thoughts<\/li><li><b>Other:<\/b>Angioedema<\/li><\/ul>"},"6":{"id":"930358-s-6","title":"Drug Name Info","sub":{"0":{"id":"930358-s-6-17","title":"US Trade Names","mono":"Aptiom<br\/>"},"2":{"id":"930358-s-6-19","title":"Class","mono":"<ul><li>Anticonvulsant<\/li><li>Dibenzazepine Carboxamide<\/li><\/ul>"},"3":{"id":"930358-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930358-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930358-s-7","title":"Mechanism Of Action","mono":"Eslicarbazepine acetate is a prodrug metabolized to eslicarbazepine, an anticonvulsant, which is thought to inhibit voltage-gated sodium channels.<br\/>"},"8":{"id":"930358-s-8","title":"Pharmacokinetics","sub":[{"id":"930358-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, oral: 1 to 4 hours<\/li><li>Bioavailability, oral: highly<\/li><li>Effects of food: no effect<\/li><\/ul>"},{"id":"930358-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding, plasma: less than 40%<\/li><li>Vd: 61 L<\/li><\/ul>"},{"id":"930358-s-8-25","title":"Metabolism","mono":"<ul><li>Intestinal Wall, Liver: 91% via first-pass<\/li><li>Eslicarbazepine (major): active<\/li><li>(R)-licarbazepine and oxcarbazepine (minor): active<\/li><li>moderate inhibitor of CYP2C19<\/li><li>inducer of CYP3A4<\/li><\/ul>"},{"id":"930358-s-8-26","title":"Excretion","mono":"<ul><li>Renal: more than 90% as eslicarbazepine and glucuronide metabolites<\/li><li>Renal clearance: 20 mL\/min<\/li><li>Dialyzable: Yes, partial removal via hemodialysis<\/li><\/ul>"},{"id":"930358-s-8-27","title":"Elimination Half Life","mono":"Eslicarbazepine: 13 to 20 hours <br\/>"}]},"9":{"id":"930358-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>may be administered as whole tablets or crushed tablets<\/li><li>may be administered with or without food<\/li><\/ul>"},"10":{"id":"930358-s-10","title":"Monitoring","mono":"<ul><li>reduction in seizure frequency is indicative of efficacy<\/li><li>serum sodium and chloride levels, especially in patients using concomitant drugs that decrease serum sodium levels; during maintenance therapy<\/li><li>liver laboratory tests at baseline<\/li><li>neurological events, including gait and coordination disturbances, nystagmus, balance, and ataxia<\/li><li>new or worsening of depression, suicidal thoughts or behavior, or unusual changes in mood or behavior<\/li><\/ul>"},"11":{"id":"930358-s-11","title":"How Supplied","mono":"<b>Aptiom<\/b><br\/>Oral Tablet: 200 MG, 400 MG, 600 MG, 800 MG<br\/>"},"13":{"id":"930358-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized.<\/li><li>This drug may decrease effectiveness of hormonal contraceptives with concurrent use. Recommend additional form of barrier birth control during treatment and for at least 1 menstrual cycle after treatment has been discontinued.<\/li><li>Side effects may include dizziness, headache, diplopia, vomiting, vertigo, ataxia, blurred vision, and tremor.<\/li><li>Instruct patient, caregivers, and families to report worsening depression, suicidal ideation, or unusual changes in behavior.<\/li><li>Advise patient to report signs\/symptoms of serious skin reactions, including Stevens-Johnson syndrome (flu-like symptoms, spreading red rash, or skin\/mucous membrane blistering) and toxic epidermal necrolysis (widespread peeling\/blistering of skin).<\/li><li>Instruct patient to report fever associated with symptoms of other organ\/system involvement (eg, rash, lymphadenopathy, hepatic dysfunction).<\/li><li>Advise patient to report symptoms of anaphylaxis or angioedema (swelling of the face, eyes, lips, tongue, or difficulty in swallowing or breathing).<\/li><li>Instruct patient to report symptoms of low sodium (eg, nausea, tiredness, lack of energy, irritability, confusion, muscle weakness or spasms, or more frequent or more severe seizures).<\/li><li>Advise patient to report symptoms of liver injury (eg, jaundice)<\/li><li>Advise patient against sudden discontinuation of drug.<\/li><\/ul>"}}}